Key facts
- Protogenix’s last known valuation is $28.0M (Dec 2024).
- It has raised $6.8M across 1 recorded rounds; the latest was Seed Round ($250K) in Dec 2025.
- Notable investors include SOSV, IndieBio, New York Ventures, Skull Diamond and Heart Capital, Center for Life Science Ventures — 8 tracked in total.
- Protogenix has filed 1 Form D with the SEC, most recently Feb 2026 ($250K sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Protogenix
Funding rounds
1 roundsAbout Protogenix
Developer of a protein manufacturing platform designed to replace mammalian cell systems used for producing complex proteins. The company offers decentralized production technology and plug-and-play processing methods that support yield protein generation for food and pharmaceutical applications, enabling producers to manufacture protein ingredients through alternative biological production processes.
- Sector
- Materials and Resources
- HQ
- Ithaca, NY, United States
- Founded
- 2021
- Employees
- 8
- Website
- proto-genix.com/
- Ownership
- Privately Held (backing)
Protogenix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Protogenix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Protogenix in its N-PORT filings yet. We sweep new filings monthly.